25,733 results match your criteria rituximab treatment


Lenalidomide in DLBCL: are we past the cell of origin?

Clin Adv Hematol Oncol 2021 May;19(5):320-325

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more treatment-resistant. However, the addition of lenalidomide to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in randomized clinical trials has shown equivocal benefit, despite phase 2 studies that suggested otherwise. These equivocal results suggest that either the cell of origin (COO) has limited importance for prescribing lenalidomide, or that lenalidomide is not the optimal agent for exploiting the vulnerability of ABC lymphomas. Read More

View Article and Full-Text PDF

Angiotensin II Type 1 Receptor Antibody Mediated Rejection Following Orthotopic Heart Transplant: A Single Center Experience.

Transplantation 2021 Feb 22. Epub 2021 Feb 22.

1Division of Cardiology, Department of Medicine 2Department of Pathology & Immunology 3Department of Developmental Biology Washington University in St. Louis, St. Louis, MO, 63130.

Background: Antibody mediated rejection (AMR) following orthotopic heart transplant (OHT) causes significant morbidity and mortality. There is limited data on antibodies to the angiotensin II type 1 receptor (AT1R-Ab) causing rejection following OHT.

Methods: This is a retrospective, single center study that presents our 2-year experience with a series of 11 patients with evidence of nonspecific graft dysfunction and pathologic levels of AT1R-Ab. Read More

View Article and Full-Text PDF
February 2021

Isotretinoin induced small vessel vasculitis: a life-threatening pulmonary-renal syndrome-a case report.

Ann Transl Med 2021 Apr;9(7):584

University of Kentucky College of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, Lexington, KY, USA.

Oral isotretinoin is a synthetic analog of vitamin - A, reserved for cases with severe resistant acne. We hereby report a case of drug-induced vasculitis (DV) from isotretinoin exposure leading to life-threatening pulmonary-renal syndrome requiring immunosuppression and plasmapheresis. A previously healthy 21-year-old female receiving oral isotretinoin presented with a 10-day history of worsening myalgias, arthralgias, and abdominal pain. Read More

View Article and Full-Text PDF

Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs: a case report.

Ann Transl Med 2021 Apr;9(7):583

Department of internal Medicine, Service of Pulmonology, Lucerne Cantonal Hospital, Lucerne, Switzerland.

We describe a case of a SARS coronavirus 2 (SARS-CoV-2) infection in a Swiss 54-years-old immunocompromised patient (lymphoma, therapy with the anti-CD20 antibody ), with initial scarce respiratory symptoms but typical coronavirus disease 2019 (COVID-19) radiological presentation, and symptoms onset during a holiday trip to Texas (USA). Three nasopharyngeal swabs in the 96 hours following hospital admission were negative, despite a CT thorax suggestive for an early stage of infection. COVID-infection was finally confirmed in the bronchoalveolar lavage (BAL) fluid, performed for exclusion of an alternative diagnosis in immunocompromised. Read More

View Article and Full-Text PDF

Granulomatosis with Polyangiitis: Recurrence or Treatment Consequences?

Eur J Case Rep Intern Med 2021 22;8(4):002448. Epub 2021 Apr 22.

Nephrology Department, Centro Hospitalar Universitário do Porto, Portugal.

Granulomatosis with polyangiitis (GPA) is the most common antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We describe the case of a 38-year-old woman with relapsing GPA who presented with intracranial hypertension, followed by the appearance of cavitated lung nodules despite treatment with azathioprine. Clinical improvement and ANCA titre reduction were observed after rituximab treatment. Read More

View Article and Full-Text PDF

Efficacy of Rituximab on Rheumatoid Leptomeningitis as the First Symptom of Rheumatoid Arthritis.

Eur J Case Rep Intern Med 2021 21;8(4):002358. Epub 2021 Apr 21.

Service de Rhumatologie, CHRU Besançon, Besançon, France.

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized mainly by arthritis, with the possible occurrence of extra-articular manifestations. We report the case of a patient who developed leptomeningitis as the first sign of RA, one year before the diagnosis of RA. Methylprednisolone 1000 mg was given intravenously. Read More

View Article and Full-Text PDF

Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.

Bone Marrow Transplant 2021 May 13. Epub 2021 May 13.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

This study compared the quality-adjusted effectiveness and costs of three treatment options for transplant-eligible patients with early progression (POD24) of follicular lymphoma. A Markov decision-analytic model using a 20-year time horizon was used to compare allogeneic stem cell transplant (alloSCT), autologous stem cell transplant (ASCT), and chemo-immunotherapy (O-CHOP). For second relapse/refractory disease, novel therapy use was modeled, including lenalidomide and rituximab/obinutuzumab, and PI3K inhibitors (PI3Ki). Read More

View Article and Full-Text PDF

Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.

Am J Case Rep 2021 May 13;22:e931107. Epub 2021 May 13.

Department of Internal Medicine, Lyon Civil Hospices, Edouard Herriot Hospital, Lyon, France.

BACKGROUND Delayed hemolytic transfusion reactions (DHTR) are life-threatening complications mostly triggered by red blood cell (RBC) transfusions in patients with hemoglobinopathy. CASE REPORT We present a case of DHTR and hyperhemolysis syndrome in a 39-year-old pregnant woman with a history of ß-thalassemia intermediate in whom the hemoglobin (Hb) level fell to 27 g/L after transfusion of 2 units of crossmatch-compatible packed RBCs. No allo- or auto-antibody formation was detected. Read More

View Article and Full-Text PDF

A woman with visual loss, amenorrhoea and polyuria: the first reported case of nodular lymphocyte-predominant Hodgkin lymphoma presenting with hypopituitarism.

Endocrinol Diabetes Metab Case Rep 2021 May 1;2021. Epub 2021 May 1.

Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Australia.

Summary: A 34-year-old woman presented 18 months post-partum with blurred vision, polyuria, amenorrhoea, headache and general malaise. Comprehensive clinical examination showed left superior temporal visual loss only. Initial investigations revealed panhypopituitarism and MRI demonstrated a sellar mass involving the infundibulum and hypothalamus. Read More

View Article and Full-Text PDF

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens.

Open Med (Wars) 2021 21;16(1):672-682. Epub 2021 Apr 21.

Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, 84131, Italy.

Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients' age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age >60 years old) with newly diagnosed and relapsed/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. Read More

View Article and Full-Text PDF

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.

Mol Ther Oncolytics 2021 Jun 3;21:158-170. Epub 2021 Apr 3.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.

Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials. However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab's antibody-dependent cellular cytotoxicity (ADCC) efficacy. Read More

View Article and Full-Text PDF

Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'.

Ann Rheum Dis 2021 May 12. Epub 2021 May 12.

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany

View Article and Full-Text PDF

Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation.

BMJ Case Rep 2021 May 12;14(5). Epub 2021 May 12.

Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK.

A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. Read More

View Article and Full-Text PDF

Reliability of generic quality-of-life instruments in assessing health-related quality of life among children and adolescents with idiopathic nephrotic syndrome: a systematic review.

Health Qual Life Outcomes 2021 May 12;19(1):144. Epub 2021 May 12.

Department of Pediatrics, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, 400001, Nigeria.

Introduction: Most of the studies reporting the negative impact of idiopathic nephrotic syndrome on health-related quality of life in children and adolescents were conducted with generic quality-of-life instruments rather than disease-specific instruments. The consistency of these studies' findings using these generic instruments is not well established.

Aim: This systematic review aims to determine the reliability of current generic quality-of-life instruments in assessing health-related quality of life among children and adolescents with idiopathic nephrotic syndrome. Read More

View Article and Full-Text PDF

[Rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma: a case report and literature review].

Zhonghua Xue Ye Xue Za Zhi 2021 Apr;42(4):338-342

Department of Hematology, Institute of Hematology, The First Affiliated Hospital of Naval Medical University, Changhai Hospital, Shanghai 200433, China.

View Article and Full-Text PDF

Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases.

Mult Scler Relat Disord 2021 May 1;52:102988. Epub 2021 May 1.

Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Background: Anti-CD20 antibody therapy may be associated with an increased risk of infections. We therefore investigated risk factors for infection in patients with demyelinating diseases treated with anti-CD20 antibody therapy.

Methods: In this retrospective uncontrolled study, patients ever treated with anti-CD20 antibodies at an academic clinic were identified through the Danish Multiple Sclerosis Registry (DMSR). Read More

View Article and Full-Text PDF

Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab.

Platelets 2021 May 12:1-2. Epub 2021 May 12.

Department of Internal Medicine, Meander Medical Centre, Amersfoort, The Netherlands.

Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy with a severe mortality and morbidity. Caplacizumab has recently been approved in the Netherlands as a new therapeutic option in patients with life-threatening organ failure due to aTTP. We describe the case of a 50 year old patient with aTTP who was referred to our hospital for treatment with caplacizumab. Read More

View Article and Full-Text PDF